RxDoctor Payments Data

Bhavna Sharma, MD

Family Medicine · Madison, ALNPI 1619921822

Payments from drug & device makers

$1,817in general payments, 2019–2025

Across 90 payments — averaging $20.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$272
  • Novo Nordisk$221
  • ZOLL Respicardia, Inc.$220
  • AstraZeneca$131
  • Pfizer$110
  • Actelion Pharmaceuticals US, Inc.$110
  • plus $755 from 22 others

What the payments were for

  • Food & beverage$1,817100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,817 in reported general payments places this provider in the 65th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$86,756
Medicare patients
221
Services billed
1,062

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide76$113,905
JardianceEmpagliflozin55$75,261
JanuviaSitagliptin Phosphate47$51,976
Janumet XrSitagliptin Phos/Metformin Hcl27$31,618
MyrbetriqMirabegron26$26,290
MounjaroTirzepatide13$19,688
EliquisApixaban12$17,840
TradjentaLinagliptin11$17,170
JanumetSitagliptin Phos/Metformin Hcl11$15,929
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$11,488
Breo ElliptaFluticasone/Vilanterol13$7,086
Spiriva RespimatTiotropium Bromide11$5,457
Atorvastatin Calcium467$4,971
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$4,244
SynthroidLevothyroxine Sodium43$3,971

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$221$113,90576 claims
MerckJanuvia, Janumet Xr, Janumet$32$99,52385 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$30$97,88877 claims
Lilly USA, LLCMounjaro$58$19,68813 claims
PfizerEliquis$110$17,84012 claims
GSKBreo Ellipta$73$7,08613 claims
AbbVieSynthroid$12$3,97143 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Madison

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →